49 results on '"Punie, K"'
Search Results
2. Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers.
3. Young oncologists’ perspective on the role and future of the clinician-scientist in oncology
4. 238P Real-world treatment (Tx) patterns in patients (pts) with HR+/HER2– metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US)
5. LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)
6. 14P Comparison of single-cell ERBB2 mRNA expression levels with HER2 status by immunohistochemistry reveals heterogeneity of the HER2-low status
7. 91P The lack of documentation of patient’s body mass index (BMI) in recent clinical trials
8. 2MO Expression levels of immune checkpoint markers (IC) in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC)
9. 40P Stromal tumor infiltrating lymphocytic infiltration in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC)
10. Corrigendum to “Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer”
11. Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future
12. Serum methylmalonic acid concentrations at breast cancer diagnosis are not associated with distant metastases
13. LBA17 Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)
14. PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment
15. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer
16. 168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study
17. Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate
18. The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series
19. Solitary pituitary metastasis from HER2-positive breast cancer treated with stereotactic radiotherapy – a case report
20. Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer
21. 257P Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
22. 258P Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC)
23. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
24. 128P Characteristics, patterns of care and outcomes of young women with breast cancer (BC) according to age, year of diagnosis and germline BRCA status (gBRCA)
25. 1561O The future of the oncology workforce since COVID-19: Results of the ESMO Resilience Task Force survey series
26. 88P Efficacy of olaparib in advanced cancers occurring in patients with germline or somatic tumor mutations in homologous recombination (HR) genes, a Belgian Precision phase II basket study
27. Detection of secondary metastatic breast cancer by measurement of plasma CA 15.3
28. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape
29. Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study
30. The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II
31. 51P The development of a predictive model for risk results of the 70-gene signature
32. The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration
33. ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer
34. ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib
35. 3MO IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemo in early triple-negative breast cancer (TNBC)
36. Treatment efficacy and predictors of durable response to capecitabine monotherapy in advanced breast cancer: Real-world evidence from a large single-centre cohort
37. Plasma markers showing differential baseline expression in relapsing versus non-relapsing patients with hormone sensitive breast tumors
38. LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)
39. 303P Use of CA 15.3 for the detection of secondary metastatic breast cancer
40. LBA17 ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
41. LBA70_PR The impact of COVID-19 on oncology professionals: Initial results of the ESMO resilience task force survey collaboration
42. 348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)
43. 148P Surgery (Sx) of the primary tumour in de novo metastatic breast cancer (BC) patients (pts) is associated with increased survival: A nationwide population-based study by the Belgian Cancer Registry (BCR) and the Belgian Society of Medical Oncology (BSMO)
44. A critical appraisal of quality indicators of breast cancer treatment in Belgium
45. Differences between breast cancer subtypes in developing metastatic disease
46. Intrahepatic mitomycin C infusion in breast cancer liver metastases
47. Efficacy of CDK 4/6 inhibition after fulvestrant in metastatic breast cancer
48. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
49. Germline TP53 pathogenic variants and breast cancer: A narrative review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.